Alzheimers

EU Reverses Course, Approves Eisai's Alzheimer's Drug After Earlier Rejection

1 month ago

In a significant shift in regulatory stance, the European Union has granted approval to Eisai Co.'s Alzheimer's treatment, marking a notable turnaround from its earlier decision to reject the drug. This development stands to impact the treatment landscape for Alzheimer’s disease and offers renewed hope for patients suffering from this debilitating condition.

Biogen Boosts Forecast as Leqembi Shows Promising Growth in Alzheimer's Treatment

2 months ago

In a significant development for the biopharmaceutical sector, Biogen Inc. has raised its financial projections for the upcoming periods due to the encouraging performance of its Alzheimer's treatment, Leqembi. The announcement came on the heels of a third-quarter earnings report, which revealed that the drug has started to gain traction in the market, signaling potential advancement in Biogen’s business trajectory amidst ongoing challenges in the healthcare industry.

Roche Faces Scrutiny Following Patient Death in Alzheimer's Clinical Trial

2 months ago

Roche Holding AG has come under intense scrutiny following the unfortunate death of a patient during its early-stage clinical trial for an experimental Alzheimer’s drug. The incident has raised concerns not only about the safety of the drug under investigation but also about the broader implications for ongoing Alzheimer's research.

Breakthrough in Alzheimer's Treatment: Lilly's New Dosing Strategy Reduces Brain Swelling Risks

2 months ago

In a significant development for Alzheimer's disease treatment, Eli Lilly and Company has unveiled promising results from a recent study that indicates a modification in dosing could reduce the risk of brain swelling associated with its Alzheimer’s therapy, donanemab. This news marks a crucial advancement in managing the side effects often associated with Alzheimer's medications, offering hope to patients and healthcare providers alike.

Revolutionary Findings: Novo's Ozempic Shows Promise in Reducing Alzheimer's Diagnoses

2 months ago

In a groundbreaking development, recent research has suggested that Novo Nordisk’s diabetes medication, Ozempic, may significantly reduce the incidence of Alzheimer's disease among patients using the drug. This insight has stirred excitement in both the medical community and pharmaceutical industry as the prevalence of Alzheimer's continues to rise globally, posing a substantial challenge to public health systems.